Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology Award from Orthopedics This Week 24.09.2024, 19:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Medacta Group 157,70 EUR -1,25 % Lang & Schwarz

Medacta Group SA / Key word(s): Miscellaneous
Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology Award from Orthopedics This Week

24.09.2024 / 19:00 CET/CEST


MEDIA RELEASE

Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology Award from Orthopedics This Week

CASTEL SAN PIETRO, September 24, 2024—Medacta Group SA ("Medacta," SIX:MOVE) announced today its NextAR Rod Optimizer has been awarded the 2024 Spine Technology Award from Orthopedics This Week. This marks the third time a Medacta spine product has received this prestigious honor after the MySpine Platform, patient-matched technology, and the NextAR Spine, Augmented Reality Surgical Application.

The unique NextAR Rod Optimizer is a sustainable and personalized solution designed to enhance intraoperative planning and provide real-time selection starting from a dozen pre-bent rods that allow thousands of solutions1 in both minimally invasive and open approaches. Spine surgeons can now benefit from an advanced solution that eliminates the need for manual rod-bending, significantly reducing the risk of breakage and subsequent revision surgeries. This innovative approach also provides a compelling alternative to systems that are based on custom-made rods, eliminating preoperative imaging, production and waiting time, with significant advantages for surgeons and patients.

“NextAR Rod Optimizer provides the most accurate and easy to deploy point of care solution for selecting personalized rods for long fusion constructs, providing the optimal rod length and contour for percutaneous or open deformity constructs,” states Lionel Metz, MD, University of California San Francisco Department of Orthopedic Surgery.

The NextAR Rod Optimizer is part of NextAR Spine and may also be used as a stand-alone technology. This innovative tool complements Medacta's comprehensive spine offering by enhancing surgical procedures with cutting-edge precision and efficiency. NextAR Rod Optimizer aims to improve patient outcomes and streamline the surgical workflow. This advanced technology exemplifies Medacta's commitment to developing innovative and sustainable solutions that support both surgeons and patients.

The possibility of having an intraoperative planning tool to select a pre-bent rod among multiple solutions has enhanced my workflow and reduced potential complications associated with traditional techniques that require manual bending,” says Dr. Itsuo Shiina, from the Department of Orthopaedic Surgery, Moriya Daiichi Hospital, Japan.

The NextAR Rod Optimizer further expands the capabilities of the award-winning NextAR Spine, an innovative technology proven to be accurate in screw placement, and to seamlessly integrate into the OR workflow, enabling the surgeon to enhance efficiency, accuracy, and versatility in spine surgery2.

NextAR Spine is a sustainable solution within Medacta’s NextAR Augmented Reality Surgical Platform for both joint replacement and spine procedures. This hardware system offers the ability to host software for multiple applications (NextAR Knee, NextAR Shoulder, NextAR Spine). It is a vital component of the MySolutions Personalized Ecosystem, a network of advanced digital solutions designed to enhance patient care and surgical outcomes.

The entire spine portfolio is supported by the comprehensive, tailored educational offerings provided by the M.O.R.E. Institute. With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on spine procedures and products with personalized high-level educational pathways. With Medacta, the surgeon is never alone.

For more information about the NextAR Rod Optimizer, please visit https://nextar-rod-optimizer.medacta.com/.

 

Contact
Gianluca Olgiati
Group Vice President Marketing
+41 91 696 60 60
media@medacta.ch

 

Medacta is a key global player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 60 countries. Follow us on Medacta TV, YouTube, LinkedIn and X.

 

RELATED TRADEMARKS
Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. MySolutions™ Personalized Ecosystem, NextAR™, NextAR™ Spine, NextAR™ Rod Optimizer, M.U.S.T.®.

REFERENCES
[1] Data on file Medacta

[2] Schwendner M, Ille S, Wostrack M, Meyer B. Evaluating a cutting-edge augmented reality-supported navigation system for spinal instrumentation. Eur Spine J. 2023 Nov 14. doi: 10.1007/s00586-023-08011-w. Epub ahead of print. PMID: 37962688.


Additional features:

File: Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1994629

 
End of News EQS News Service

1994629  24.09.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1994629&application_name=news&site_id=boersennews_de~~~d41e2cc8-bdcb-47ba-bb51-c77a04513666
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer